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ABSTRACT
The targeting of specific genes responsible from onset and 
progression of kidney diseases offer a new therapeutic strategy 
in the field of renal gene therapy. The altered expression 
of platelet derived growth factor (PDGF) is an important 
marker of renal diseases. In this study, we investigated in vitro 
gene silencing efficiency of chitosan nanoplexes containing 
PDGF-b and PDGFr-β targeted sirnAs in the kidney cell lines 
including HEk-293 and MDCk and delivery to the kidney 
as an in vivo delivery system. As a result, PDGF-b expression 
was significantly inhibited by co-delivery of chitosan/siPDGF-
b+siPDGFr-β nanoplexes prepared using in the different 
weight ratios (10/1, 20/1 and 50/1). When 20/1 and 50/1 weight 
ratios of chitosan nanoplexes were i.v. injected to rats, chitosan/
FITC-siPDGFb nanoplexes were reached to kidney tissue at 4 
h after intravenous injection. These results suggest that delivery 
of sirnA using chitosan nanoplexes may be effective for the 
therapy of kidney diseases.
Keywords: sirnA, PDGF-b, PDGFr-β, chitosan, nanoplexes, 
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INTRODUCTION
kidney diseases are an important health problem in 
worldwide. Diabetic and non-diabetic kidney diseases 
including glomerular, vascular, tubulointerstitial, cystic 
diseases are cause of kidney diseases (1). Classic pharmacologic 
approaches have been widely used for treatment of kidney 
diseases. recently, the targeting of specific genes responsible 
from onset and progression of kidney diseases offer a new 
therapeutic strategy in the field of renal gene therapy (2). One 
of these strategies involves targeting mrnA by using small 
interfering rnAs (sirnAs), which induce sequence-specific 
gene silencing. Several studies reported that the direct 
delivery of naked sirnA has sufficient effect in occurring of 
rnA interference (rnAi) mechanism (3). However, if sirnA 
is not chemically modified or use as a free form without 
delivery system, it has little chance in the in vivo applications. 
The most important limitation of sirnAs is that they have 
poor pharmacokinetic profile due to easily degraded by 
nucleases. sirnAs have short half-life in serum. sirnAs are 
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small size in the 21-23 nucleotide double-stranded structure. 
When administered as systemically,  they are rapidly excreted 
through urine. Thus, the rapid clearance by kidneys reduces 
half-life of sirnA (4). Although this situation is undesired 
effect, kidney diseases may provide an important target for 
sirnA therapy (2). One of the other major difficulties for 
sirnA therapy is not freely cross the cell membrane due to 
its large molecular weight (~13 kDa) and polyanionic nature 
(~40 negative phosphate charges) (5). Therefore, efficient 
delivery systems in the in vitro and in vivo conditions are 
prerequest for effective gene silencing by sirnA in target 
cells. 
The delivery of sirnAs to the kidney can be lead to better 
therapeutic outcomes because of reducing repeated 
administrations or dose and minimizing side effects and 
toxicity (6). Chitosan is a cationic biopolymer that has many 
advantages in terms of specific delivery, cellular uptake and 
intracellular trafficking to improve the therapeutic effect 
of sirnA (7). The many studies using chitosan as delivery 
system for sirnA have been made in our laboratory. 
Previously, we reported that chitosan is an efficient delivery 
system for nucleic acid-based drugs (8, 9).  
There are several reports related with targeting to the kidney 
with nanoparticle based therapeutics. Choi et al. showed that 
PEGylated gold nanoparticles (AunPs) in the under of 100 
nm particle size can be targeted the mesangium of the kidney 
(10). Thus, they have highlighted importance for the therapy 
of kidney diseases of the accumulation of PEGylated Au nPs 
in the kidneys. 
zuckerman et al. reported efficient delivery of sirnA to the 
glomerular mesangium by intravenously administration of 
polycationic cyclodextrin nanoparticles containing sirnA. 
They showed suppression of enhanced green fluorescent 
protein (EGFP) in the mesangial cells following intravenous 
administration of nanoparticles (11). 
Gao et al. showed to target sirnA specifically to the proximal 
tubule epithelial cells (PTECs) in the kidneys in mice when 
administered intravenously of chitosan/sirnA nanoparticles 
to the megalin gene knockout mice. They have reported 
chitosan nanoparticles are potential carrier for knockdown 
of specific genes in PTECs. (12).
Platelet derived growth factor (PDGF) is one of the best 
characterized growth factors in kidney diseases. PDGFs are 
important autocrine and paracrine mitogens and survival 
factors in many cells of mesenchymal origin (13). PDGF-b 
is a ligand for PDGF receptors α and β (PDGFr-α and 
PDGFr-β).  The abnormal expressions of PDGF-b and 
PDGFrs are lead to development of glomerular diseases 
in human and experimental models (13). The targeted 
therapeutic strategies to PDGFs offer promising approaches 
to kidney diseases (6). Here, we investigated in vitro PDGF-b 
gene silencing efficiency of prepared chitosan nanoplexes 
with sirnAs targeting not only PDGF-b but also its receptor 
PDGFr-β in the kidney cell lines and also targeting to the 
kidney of chitosan nanoplexes as in vivo delivery system. 
MATERIALS AND METHODS
Chemicals
siPDGF-b and siPDGFr-β were obtained from Qiagen (uSA). 
FITC-labelled siPDGF-b was obtained from Dharmacon 
(uSA). Chitosan (75 kDa; 75%–85% deacetylation) was 
purchased from Sigma (St. louis, MO, u.S.A.). All the 
substances used in this study were of molecular grade.
The Control and Preparation of Chitosan/siRNA 
Nanoplexes
Chitosan/sirnA nanoplexes were formed by electrostatic 
interactions between cationic chitosan polymer and anionic 
sirnA molecule. low molecular weight chitosan stock 
solution (2.5 mg/ml) was prepared in 1% acetic acid solution 
and filtered through 0.45 µm membrane filter. Chitosan/
sirnA nanoplexes were prepared in different weight ratios 
(10/1, 20/1 and 50/1) by adding into chitosan solutions in 
different amounts of sirnA solutions in the constant amount. 
The mixed solution was vortexed and incubated for 30 min 
at room temperature for forming nanoplexes completely. 
The formation of nanoplexes was checked by agarose gel 
electrophoresis using 2% gel at 200v/80 mA (14).
Particle size and zeta potential values of chitosan/sirnA 
nanoplexes in PbS were measured by photon correlation 
spectrosccopy using a zetasizer nanozS (Malvern 
Instruments, nanozS zEn 3600, uk) after dispersed in PbS 
(pH 7.4). All measurements were carried out in triplicate 
with a temperature equilibration time of 1 minute at 25°C.
In vitro Transfection and Gene Silencing Studies
Human Embryonic kidney 293 (HEk293) and Madin-
Darby Canine kidney (MDCk) cells, the commonly used 
kidney cell lines, were obtained from the American Type 
Culture Collection. These cells were utilized because they 
constitutively express PDGF in the presence of 20% fetal 
bovine serum (FbS) in medium (15). Cells maintained 
in Dulbecco’s modified Eagle medium (DMEM) 
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supplemented with 20% FbS and 100 Iu/ml penicillin and 
50 mg/ml streptomycin in a humidified in incubator 5% CO2 
atmosphere at 37°C and were passaged each three days. Cells 
were plated in 24 well plates at a cell density of 5 x105 cells/
well and incubated overnight. Transfections were performed 
on cells that were approximately 70% confluent. Chitosan/
siPDGF-b and siPDGFr-β nanoplexes in the different 
weight ratios (10/1, 20/1 and 50/1) were added to cells and 
incubated for 48 and 72 hours for transfection. 
PDGF-B Quantification by ELISA
ElISA for the detection of PDGF-b protein expression levels 
in cell culture supernatants were performed according to 
the manufacturer’s instructions using a sandwich ElISA 
(uSCn life, China), with absorbance being determined 
by spectrophotometry at 450 nm. Calibration curve was 
generated using this standard, at concentrations between 0 
and 500 pg/ml. All experiments were repeated thwice and 
data were expressed as mean SEM. 
In vivo Study of Chitosan/siFITC-labeled PDGF-B 
Nanoplexes to the Kidney
In vivo targeting study to the kidney of chitosan/sirnA 
nanoplexes, 20 µg FITC labelled PDGF-b sirnA was 
formulated with chitosan in 20/1 and 50/1 weight ratios. 
Chitosan/FITC-siPDGF-b nanoplexes were injected into tail 
vein of Sprague-Dawley rats. rats were sacrificed 4 hours after 
the injection and kidneys were collected and snap frozen in 
liquid nitrogen. The frozen tissue was used for cryo-sections. 
Sections were examined by fluorescence microscopy. All 
procedures of animal work were approved by Animal Ethic 
Committee of Inonu university (2012/A-76). 
Statistical Analysis
The results are expressed as the mean ± standard deviation. 
Statistical analysis of differences between groups was 
performed using an unpaired Student’s t-test by SPSS 16.0. P 
values less than 0.05 were considered statistically significant.
RESULTS and DISCUSSION
Characterization of Nanoplexes
sirnAs have anionic phosphodiester backbones with negative 
charge ratios and therefore they may interact electrostatically 
with cationic chitosan polymer to form chitosan nanoplexes 
(5, 16). After preparation, the formation of chitosan/
siPDGF-b+siPDGFr-β nanoplexes were checked by agarose 
gel electrophoresis. no free sirnA were detected on the gel 
(Fig.1). 
Figure 1. Agarose gel analysis of the chitosan/siPDGF-
b+siPDGFr-β nanoplexes in the different weight ratios (1. 
Free sirnA, 2-5. 10/1, 20/1, 30/1, 50/1). 
The physicochemical properties of the nanoplexes are the 
major factor of the gene silencing efficiency (17). The mean 
diameters and zeta potentials of all nanoplexes were analyzed 
(Table 1). The zeta potential values of chitosan/siPDGF-b 
nanoplexes (10/1-50/1) were ranged from +10.1 to +28.7 
mv and their particle sizes were ranged from 262 to 514 nm. 
The zeta potential values of chitosan/siPDGF-b+siPDGFr-β 
nanoplexes (10/1-50/1) were ranged from +7.8 to +22.3 mv 
and their particle sizes were ranged from 261 to 341 nm. The 
zeta potential and particle size values of nanoplexes increased 
with increasing amount of chitosan. numerous studies have 
reported that particle size is an important parameter for 
cellular uptake in targeted drug delivery (7, 10, 16). When 
the particles have average diameter between 200 and 500 nm, 
they can be introduced into target cells by endocytosis and 
subsequently permeate the nuclear membranes through the 
nuclear pores (18, 19). 
Table 1. Particle size and zeta potential measurements of 
chitosan/sirnA nanoplexes.
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The Suppression of PDGF-B Expression in Kidney Cells
PDGF is one of the best described growth factors in kidney 
diseases. Changed expression levels of PDGF and its receptors 
lead to many renal diseases. Therefore, specific anti-PDGF 
therapy approaches have been developed for prevention 
of renal diseases (13). by the aim of this, we tried to 
knockdown PDGF-b expression level with chitosan/siPDGF-
b+siPDGFr-β nanoplexes in the kidney epithelial cells. 
In vitro gene silencing study, we firstly investigated endogenous 
PDGF-b expression in the MDCk and HEk293 cells. 
Endogenous PDGF-b expression was measured as 214 pg/
ml in HEk293 cells and 187 pg/ml in MDCk cells. Then, 
to investigate the PDGF-b gene silencing effect of chitosan/
siPDGF-b, chitosan/siPDGFr-β and chitosan/siPDGF-
b+siPDGFr-β nanoplexes in both cell lines, nanoplexes in 
the different weight ratios (10/1-50/1) were transfected to cells 
and incubated 48 h (Figs. 2-5).  After transfection, PDGF-b 
expression was decreased as depend on weight ratio of 
nanoplexes and co-delivery of siPDGF-b and siPDGFr-β in the 
both cells. As shown in Figs. 2-5, the co-delivery of siPDGF-b 
and siPDGFr-β provided high PDGF-b downregulation 
effect, comparing to single formulations. Moreover, the highest 
PDGF-b downregulation effect was found in the HEk293 
and MDCk cells treated with prepared 50/1 weight ratio 
nanoplexes, respectively 71% and 57%. Gao et al. transfected 
chitosan/sirnA nanoparticles containing 50 nM sirnA at n/
P=60 and n/P=10 ratio to the EGFP expressing H1299 cell line 
(12). In vitro transfection results showed EGFP knockdown by 
n/P ratio of 60 was higher than that of 10. These results were 
similar to our results. They were investigated silencing of gene 
expression in MDCk cells of chitosan nanoparticles containing 
sirnA targeted aquaporin 1 (AQP1), which is predominantly 
expressed in PTECs. Chitosan nanoparticles containing two of 
three sirnA sequences designed to target mouse AQP1 showed 
a strong knockdown mrnA and protein expression. From the 
above results, it was suggested that co-formulation of sirnAs 
targeting growth factor and its receptor would promote gene 
silencing efficiency.
Figure 2. PDGF-b gene silencing efficiency of the chitosan/
siPDGF-b+siPDGFr-β nanoplexes which was determined 
by ElISA in HEk 293 cells.
Figure 3. PDGF-b gene silencing efficiency of the chitosan/
siPDGF-b+siPDGFr-β nanoplexes which was determined 
by ElISA in MDCk cells. 
Figure 4. Percent PDGF-b gene silencing in the HEk293 cell 
line.
Figure 5. Percent PDGF-b gene silencing in the MDCk cell 
line.
In Vivo Delivery of Chitosan/FITC-siPDGF-B Nanoplexes 
to Kidney 
To test whether or not reaching or accumulating to the 
kidney of chitosan/sirnA nanoplexes, chitosan/FITC-
labelled siPDGF-b nanoplexes were systematically 
administered to rats formulated with chitosan in 20/1 and 
50/1 weight ratios. We examined fluorescence intensity of the 
kidneys by fluorescence microscopy analysis after at 4 hours 
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of transfection.  As shown in Figure 6, strong fluorescence 
intensity was shown in kidney tissue at 4 h after intravenous 
injection of chitosan/FITC-siPDGF-b nanoplexes. In terms 
of the fluorescence intensity between 20/1 and 50/1 weight 
ratios was not seen any difference. A lower fluorescence 
intensity in kidney was found at 4 h after intravenous 
injection of free FITC-siPDGF-b. Gao et al. reported that 
when chitosan/Cy5-labeled sirnA nanoparticles were 
imaged by fluorescence living imaging system, Cy5 signals 
were apparent in the kidney after 20-30 min and peaked at 
3-4 hrs, with some signal remaining more than 48 hrs post 
injection (12). naked sirnA peaked at an earlier time point 
(30 min) and disappeared almost 1 hr to 3 hrs post injection. 
These results are in agreement with our results obtained by 
fluorescence microscopy. Shimizu et al. developed to target 
delivery to kidney mesangium of mitogen-activated protein 
kinase 1 (MAPk1) sirnA containing poly (ethylene glycol)-
poly (l-lysine) nanoparticles (20). They showed strong 
fluorescence in both kidneys at 3.5 hrs after peritoneal 
injection of Cy5-labeled sirnA nanoparticles and detected 
sirnAs in the blood circulation for a prolonged time. Gao 
et al. suggested that chitosan/sirnA complexes accumulated 
in the kidneys after intraperitoneal administration and 
sirnA level in the kidney remained very high even after 24 
hrs (21). Chitosan prolonged the blood circulation time of 
sirnA. Salva et al. showed the biodistribution of chitosan/
sivEGF complexes to many tissues including kidney, liver, 
brain, spleen, lungs and muscle. Especially, chitosan/sivEGF 
complexes were reached to breast tumour within 15 min post 
injection (22). 
Figure 6. Fluorescence microscopy images of rat kidney at 
the 4 hours after i.v. administration of free sirnA (a) and 
chitosan/FITC-siPDGF-b nanoplexes in the 20/1 (b) and 
50/1 (c) weight ratios. Thin, thick arrows and arrow head 
were shown tubules, blood vessels, glomeruli, respectively.
CONCLUSION
In conclusion, chitosan/sirnA nanoplexes may help to 
clarification of molecular mechanisms and therapy of kidney 
diseases. Our results suggested that the co-delivery of platelet 
derived growth factor and its receptor by chitosan nanoplexes 
would be a promising approach for enhance of gene silencing 
efficiency.
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In vitro PDGF-B gen susturma çalışmaları ve siRNA’nın rat 
böbreğine kitosan/siRNA nanopleksleri kullanılarak in vivo 
taşınması
ÖZ
böbrek hastalıklarının başlaması ve ilerlemesinden sorumlu 
olan spesifik genlerin hedeflenmesi renal gen tedavisi alanında 
yeni bir terapötik stratejidir. Platelet-türevi büyüme faktörünün 
(PDGF) ekspresyonunun değişmesi böbrek hastalıklarının 
önemli belirteçlerinden biridir. bu çalışmada, PDGF-b ve 
PDGFr-β hedefli sirnA içeren kitozan nanoplekslerin HEk-
293 ve MDCk hücre hatlarında in vitro susturma etkinlikleri 
ve in vivo olarak böbreğe taşınması araştırılmıştır. Sonuç 
olarak, farklı oranlarda (10/1, 20/1 ve 50/1) hazırlanan 
kitozan/siPDGF-b+siPDGFr-β nanoplekslerinin PDGF-b 
ekspresyonunu anlamlı olarak inhibe ettiği görülmüştür. 20/1 ve 
50/1 oranında hazırlanan kitozan nanoplekslerin sıçanlara i.v. 
enjeksiyonundan 4 saat sonra FITC-siPDGF-b nanoplesklerin 
böbrek dokusuna ulaştığı gözlenmiştir. bu sonuçlardan yola 
çıkılarak, böbrek hastalıklarının tedavisinde sirnA taşınması 
için kitozan nanoplekslerin etkili olabileceği görülmüştür.
Anahtar kelimeler:  sirnA, PDGF-b, PDGFr-β, kitozan, 
nanopleks, böbrek
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